Search

1 to 10 of 473
Sort by

Event
SITC CPG Webinar – Case Studies in Immune Checkpoint Inhibitor-related Adverse Events

This webinar is supported, in part, by independent medical education grant funding from Amgen and Merck & Co., Inc. (as of 6/7/21) #ImmuneCheckpointInhibitors #AdverseEvents

 10-06-2021 | 19:00 - 20:00 ET


Event
CPG Webinar – Practical Management Pearls for Immune Checkpoint Inhibitor-related Adverse Events

This webinar is supported, in part, by independent medical education grant funding from Amgen and Merck & Co., Inc. (as of 6/7/21) #ImmuneCheckpointInhibitors #ClinicalPracticeGuideline #AdverseEvents

 09-16-2021 | 11:30 - 12:30 ET


Library Entry
SITC Clinical Practice Guideline: Immune Effector Cell-related Adverse Events - Recorded Webinar and Presentation Slides

On March 5, 2021, leading experts in cancer immunotherapy presented an overview of the publication "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events" during a live webinar. The recorded webinar and presentation slides are...

2 attachments



Library Entry
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

Immune effector cell (IEC) therapies offer durable and sustained remissions in significant numbers of patients with hematological cancers. While these unique immunotherapies have improved outcomes for pediatric and adult patients in a number of disease states, as ‘living drugs,’ their toxicity...


Web Page
SITC Publishes Clinical Practice Guideline on Immune Effector Cell-related Adverse Events

FOR IMMEDIATE RELEASE Dec. 18, 2020 MILWAUKEE – The Society for Immunotherapy of Cancer (SITC), the world’s leading member-driven organization dedicated solely to cancer immunotherapy, is pleased to announce the publication of a clinical practice guideline for the management of cell therapy...


Library Entry
Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab

Colitis is one of the common immune-related adverse events that leads to morbidity and treatment discontinuation of immunotherapy. The clinical presentation, endoscopic and histopathological features and best management of this toxicity are not well defined. The authors conclude that clinically...


Library Entry
Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management

The risk–benefit calculation for corticosteroid administration in the management of COVID-19 is complex and urgently requires data to inform the decision. The neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammation associated with poor prognosis in both COVID-19 and cancer....


Library Entry
Efficacy and immune-related adverse event associations in avelumab-treated patients

Adverse events (AEs) of special interest that arise during treatment with immune checkpoint inhibitors, including immune-related AEs (irAEs), have been reported to be associated with improved clinical outcomes. The authors analyzed patients treated with avelumab from the JAVELIN Solid Tumor and...


Library Entry
Case of Merkel cell carcinoma in a patient with pre-existing ILD

Merkel cell carcinoma (MCC) is a rare neuroendocrine tumor of the skin with high rates of local recurrence and distant metastases despite treatment with traditional cytotoxic chemotherapies. The recent advances in immunotherapy, including the use of immune checkpoint blockade (ICB) has...